Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

被引:177
作者
Wimberger, Pauline
Lehmann, Nils
Kimming, Rainer
Burges, Alexander
Meier, Wemer
Du Bois, Andreas
机构
[1] Univ Essen Gesamthsch, Dept Gynecol & Obstet, D-45122 Essen, Germany
[2] Univ Essen Gesamthsch, Inst Med Informat Biometry & Epidemiol, Essen, Germany
[3] Univ Munich Grosshadern, Dept Gynecol & Obstet, Munich, Germany
[4] Evangel Krankenhaus Dusseldorf, Dept Gynecol & Obstet, Dusseldorf, Germany
[5] HSK Dr Horst Schmidt Klin Wiesbaden, Dept Gynecol & Gynecol Oncol, Wiesbaden, Germany
关键词
ovarian neoplasm; surgery; prognostic factor; residual tumor;
D O I
10.1016/j.ygyno.2007.02.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background. No residual tumor as result of prinnary surgery in advanced ovarian cancer is known as one of the most important prognostic factors. Purpose. To evaluate the impact of different prognostic factors for surgical outcome and to evaluate the impact of surgical Outcome Oil survival. Methods. Surgical data as well as survival data were documented throughout the multi-centerprospective randomized phase III trial (OVAR-3) of the AGO-OVAR and were used for this exploratory analysis. In this study 798 patients with FIGO IIB-IV were first operated then randomized and homogenously treated with cisplatin/paclitaxel or carboplatin/paclitaxel. Only patients with complete surgical data (n = 761) entered this analysis. Results. Multivariable logistic regression analysis showed a significant decrease of probability for complete debulking without any macroscopic residual tumor for higher pre-operative minor load (OR 0.32; 95% CI 0.17-0.61), higher FIGO stage (OR 0.22; 95% CI 0.13-0.39), worse performance status (OR 0.57; 95% CI 0.38-0.86), advanced age (OR 0.78; 95% CI 0.65-0.94) and presence of peritoneal carcinornatosis (OR 0.17; 95% CI 0.10-0.28). Surgery in centers with surgeons who performed comprehensive surgical debulking including retroperitoneal lytriphadenectoiny and peritoneal stripping was associated with higher rates of complete clebulking compared to surgery in other centers (32.8% vs. 22.9%, p=0.007). This resulted in a markedly improved overall survival U3=0.045). This effect was held true after adjustment for prognostic factors (HR 0.77, 95% CI 0.63-0.94, p=0.012). Conclusion. Post-operative residual turnor is one of the most important independent prognostic factor for survival. Our results Suggest an advantage for aggressive primary surgery and complete debulking. This surgical goal was achieved more often in experienced centers. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 28 条
[1]
*AGO OVAR, 2005, INT GUID GERM CANC A
[2]
[Anonymous], 1987, Am J Obstet Gynecol, V156, P263
[3]
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[4]
Systematic lymphadenectomy in advanced epithelial ovarian cancer: Two decades of uncertainty resolved [J].
Chambers, SK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (08) :548-549
[5]
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? [J].
Chi, D. S. ;
Eisenhauer, E. L. ;
Lang, J. ;
Huh, J. ;
Haddad, L. ;
Abu-Rustum, N. R. ;
Sonoda, Y. ;
Levine, D. A. ;
Hensley, M. ;
Barakat, R. R. .
GYNECOLOGIC ONCOLOGY, 2006, 103 (02) :559-564
[6]
Cox DR., 1984, ANAL SURVIVAL DATA
[7]
The role of surgery in advanced and recurrent ovarian cancer [J].
du Bois, A. ;
Harter, P. .
ANNALS OF ONCOLOGY, 2006, 17 :X235-X240
[8]
Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer [J].
du Bois, A ;
Rochon, J ;
Lamparter, C ;
PFisterer, J .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (02) :183-191
[9]
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].
du Bois, A ;
Lück, HJ ;
Meier, W ;
Adams, HP ;
Möbus, V ;
Costa, S ;
Bauknecht, T ;
Richter, B ;
Warm, M ;
Schröder, W ;
Olbricht, S ;
Nitz, U ;
Jackisch, C ;
Emons, G ;
Wagner, U ;
Kuhn, W ;
Pfisterer, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330
[10]
Procedures required to accomplish complete cytoreduction of ovarian cancer: Is there a correlation with "biological aggressiveness" and survival? [J].
Eisenkop, SM ;
Spirtos, NM .
GYNECOLOGIC ONCOLOGY, 2001, 82 (03) :435-441